Novogene Announces Joint Venture with AITbiotech to Establish Next-Gen Sequencing Center in Singapore
– NovogeneAIT Genomics Singapore will use Illumina’s latest HiSeq X Ten sequencing system to deliver NGS services to ASEAN and South Asia Region –
BEIJING and SINGAPORE, September 7, 2016 – Novogene Corporation Ltd, a leading global next-generation sequencing (NGS) services and genetics diagnostic company, announced today a joint venture with AITbiotech Pte Ltd, a Singapore-based NGS products and services company, to establish a high-throughput (HTP) next-generation sequencing and R&D Centre in Singapore. The Singapore center, NovogeneAIT Genomics Singapore, will deliver NGS services using Illumina’s latest HiSeq X Ten sequencing system.
NovogeneAIT Genomics Singapore, which will include a team of NGS professionals highly skilled in both wet-lab and bioinformatics, will provide cutting edge NGS and research services to the Association of Southeast Asian Nation (ASEAN) and South Asia region. Under the joint venture, Novogene will invest in research and development of next-generation genetic testing products and services, especially in oncology. NovogeneAIT Genomics Singapore will embark on research and development collaborations with leading research institutes in Singapore. It is presently in discussions with such institutes and expects to announce initial collaborations in the near future, including a couple of large projects with a research entity in Singapore for the sequencing of whole human genomes.
“I am very excited and pleased to announce this significant joint venture and the formation of NovogeneAIT Genomics Singapore,” stated Dr. Ruiqiang Li, CEO of Novogene Corporation. “Our joint venture with AITbiotech represents a key milestone in Novogene’s strategy to become a truly global high-throughput next-generation sequencing services provider. With the addition of this center, we will now have three HTP NGS centers around the world, including China and the U.S.”
“We are extremely excited about the opportunity to work with a leading high-throughput next-generation sequencing services company like Novogene,” said Alex Thian, AITbiotech CEO. “AITbiotech sees this joint venture as a model of collaboration between a global company and a smaller local enterprise to jointly penetrate the large, complex ASEAN and South Asian scientific services and diagnostics markets. Our locally based technical and business expertise, as well as our established relationships in the region, will help Novogene optimize its investment and expedite business development for NovogeneAIT Genomics Singapore. This investment will be an important addition to the genomics research infrastructure in Singapore. It will help to accelerate and increase the scope of genomics data generation by public research institutions in a very significant manner.”
AITbiotech is a leading Genomic Services and MDx company based in Singapore. Founded by Alex Thian in 2008, it has a core molecular services and R&D laboratory in Singapore managed by a team of experienced biotechnologists. It provides a complete suite of Genomic Services including Capillary Sequencing, Next-generation Sequencing Services, Bioinformatics Services and customized molecular services to the research, healthcare and biomedical industries in Singapore and Asia. AITbiotech is also an ISO 13485 certified company which manufactures and distributes its own line of real-time PCR pathogen detection assays branded as abTESTM in the Asian and European markets. For more information, please visit our website: www.aitbiotech.com.
About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. Novogene delivers unsurpassed data quality to support our customers’ research goals. Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world-leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise and experience with 32 NGS-related patents, as well as over 580 research papers with total impact factor at more than 4090, including publications in first tiers journals such as Cell, Nature and Science.
For more information, please visit our website: en.novogene.com